Literature DB >> 10559010

3-deazaadenosine prevents adhesion molecule expression and atherosclerotic lesion formation in the aortas of C57BL/6J mice.

G Walker1, A C Langheinrich, E Dennhauser, R M Bohle, T Dreyer, J Kreuzer, H Tillmanns, R C Braun-Dullaeus, W Haberbosch.   

Abstract

Adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) play an important role during the development of atherosclerosis. 3-Deazaadenosine (c(3)Ado), an adenosine analogue, inhibits endothelial-leukocyte adhesion and ICAM-1-expression in vitro. We hypothesized that c(3)Ado is able to prevent the expression of adhesion molecules and atherosclerotic lesion formation in female C57BL/6J mice. The animals were placed on an atherogenic diet with or without c(3)Ado for 9 weeks. Frozen cross sections of the proximal ascending aorta just beyond the aortic sinus were stained with oil red O, hematoxylin, and elastic van Gieson's stains and were analyzed by computer-aided planimetry for fatty plaque formation and neointimal proliferation. Monoclonal antibodies against CD11b (macrophages), VCAM-1, and ICAM-1 were used for immunohistochemistry. Mice on the atherogenic diet demonstrated multiple (5.4+/-1.6 per animal) lesions covering 3.4+/-2.8% of the endothelium and a marked neointima when compared with control mice (4501+/-775 versus 160+/-38 microm(2), P<0.001). Mice on the cholesterol-rich diet without c(3)Ado showed strong endothelial coexpression of ICAM-1 and VCAM-1. Moreover, there was a 10-fold increase in monocyte accumulation on the endothelial surface (33. 3+/-4.9 versus 3.8+/-1.2, P<0.004). In contrast, in mice treated with c(3)Ado, expression of ICAM-1 and VCAM-1 as well as monocyte adhesion and infiltration were almost completely inhibited. Furthermore, these mice did not show any fatty streak formation or neointima formation (125+/-32 microm(2)). Our results demonstrate that c(3)Ado can inhibit diet-induced fatty streak formation and the expression of endothelial ICAM-1 and VCAM-1 in C57BL/6J mice. This may provide a novel pharmacological approach in the prevention and treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559010     DOI: 10.1161/01.atv.19.11.2673

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  CD73 represses pro-inflammatory responses in human endothelial cells.

Authors:  Jana Kg Grünewald; Anne J Ridley
Journal:  J Inflamm (Lond)       Date:  2010-02-05       Impact factor: 4.981

2.  The S-adenosyl homocysteine hydrolase inhibitor 3-deaza-adenosine prevents oxidative damage and cognitive impairment following folate and vitamin E deprivation in a murine model of age-related, oxidative stress-induced neurodegeneration.

Authors:  Thomas B Shea; David Ashline; Daniela Ortiz; Shelia Milhalik; Eugene Rogers
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production.

Authors:  Min-Woong Kang; Hee-Jung Song; Shin Kwang Kang; Yonghwan Kim; Saet-Byel Jung; Sungju Jee; Jae Young Moon; Kwang-Sun Suh; Sang Do Lee; Byeong Hwa Jeon; Cuk-Seong Kim
Journal:  Korean J Physiol Pharmacol       Date:  2015-04-30       Impact factor: 2.016

4.  Impaired Endothelial Nitric Oxide Synthase Homodimer Formation Triggers Development of Transplant Vasculopathy - Insights from a Murine Aortic Transplantation Model.

Authors:  Rupert Oberhuber; Gregor Riede; Benno Cardini; David Bernhard; Barbara Messner; Katrin Watschinger; Christina Steger; Gerald Brandacher; Johann Pratschke; Georg Golderer; Ernst R Werner; Manuel Maglione
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

Review 5.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.